NASDAQ:BMRA

Biomerica (BMRA) Competitors

$1.28

-0.09 (-6.57%)

(As of 06/1/2023 ET)

Compare

Today's Range: $1.28
▼
$1.40
50-Day Range: $1.12
▼
$1.99
52-Week Range: $1.08
▼
$5.25

Volume: 27,716 shs
Average Volume: 39,292 shs
Market Capitalization: $21.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

BMRA vs. OCX, AWH, TRIB, CDIO, ICCC, NYMX, MYMD, VBIV, SNCE, and IMPL

Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include OncoCyte (OCX), Aspira Women's Health (AWH), Trinity Biotech (TRIB), Cardio Diagnostics (CDIO), ImmuCell (ICCC), Nymox Pharmaceutical (NYMX), MyMD Pharmaceuticals (MYMD), VBI Vaccines (VBIV), Science 37 (SNCE), and Impel Pharmaceuticals (IMPL). These companies are all part of the "medical" sector.

Biomerica vs.

Biomerica (NASDAQ:BMRA) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.

: Biomerica has a beta of -0.62, indicating that its share price is 162% less volatile than the S&P 500. Comparatively, OncoCyte has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.
: In the previous week, Biomerica and Biomerica both had 1 articles in the media. Biomerica's average media sentiment score of 1.00 beat OncoCyte's score of 0.63 indicating that Biomerica is being referred to more favorably in the media.
Company Overall Sentiment
Biomerica Positive
OncoCyte Positive
: Biomerica received 136 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 67.82% of users gave Biomerica an outperform vote while only 12.50% of users gave OncoCyte an outperform vote.
Company Underperform Outperform
Biomerica Outperform Votes
137
67.82%
Underperform Votes
65
32.18%
OncoCyte Outperform Votes
1
12.50%
Underperform Votes
7
87.50%
: 22.0% of Biomerica shares are owned by institutional investors. Comparatively, 81.2% of OncoCyte shares are owned by institutional investors. 15.7% of Biomerica shares are owned by company insiders. Comparatively, 6.7% of OncoCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: OncoCyte has a consensus target price of $1.11, suggesting a potential upside of 388.58%. Given OncoCyte's higher probable upside, analysts plainly believe OncoCyte is more favorable than Biomerica.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
OncoCyte
0 Sell rating(s)

2 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.33
: Biomerica has a net margin of -74.56% compared to OncoCyte's net margin of -787.97%. OncoCyte's return on equity of -34.08% beat Biomerica's return on equity.
Company Net Margins Return on Equity Return on Assets
Biomerica -74.56% -95.15% -70.12%
OncoCyte -787.97% -34.08% -15.49%
: Biomerica has higher revenue and earnings than OncoCyte.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biomerica $18.87 million 1.14 -$4.53 million -$0.54 -2.37
OncoCyte $875 thousand 31.04 -$72.90 million N/A N/A

Company	Overall Sentiment
Biomerica	Positive
OncoCyte	Positive

Company	Underperform	Outperform
Biomerica	Outperform Votes 137 67.82%	Underperform Votes 65 32.18%
OncoCyte	Outperform Votes 1 12.50%	Underperform Votes 7 87.50%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
OncoCyte	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-74.56%	-95.15%	-70.12%
OncoCyte	-787.97%	-34.08%	-15.49%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$18.87 million	1.14	-$4.53 million	-$0.54	-2.37
OncoCyte	$875 thousand	31.04	-$72.90 million	N/A	N/A

Summary

Biomerica and OncoCyte tied by winning 7 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMRA vs. The Competition

Export to Excel

Metric	Biomerica	Diagnostic substances Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.52M	$2.27B	$4.54B	$6.20B
Dividend Yield	N/A	0.80%	2.42%	6.15%
P/E Ratio	-2.37	27.00	100.63	11.94
Price / Sales	1.14	695.58	3,636.66	95.58
Price / Cash	N/A	4,388.12	90.91	108.26
Price / Book	1.97	20.63	5.15	7.27
Net Income	-$4.53M	$27.00M	$117.81M	$193.48M
7 Day Performance	-16.34%	-0.32%	3.21%	2.60%
1 Month Performance	-5.19%	-0.12%	3.14%	3.08%
1 Year Performance	-64.25%	-12.04%	23.11%	1.73%

Biomerica Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCX OncoCyte	2.4488 of 5 stars	$0.22 +4.7%	$1.11 +400.9%	-80.2%	$26.49M	$960,000.00	0.00	N/A	Gap Down
AWH Aspira Women's Health	1.6541 of 5 stars	$3.29 -6.0%	$30.00 +811.9%	-63.7%	$27.41M	$8.18M	-0.25	106	Gap Down
TRIB Trinity Biotech	1.5711 of 5 stars	$0.90 -2.2%	N/A	-34.5%	$34.30M	$74.78M	-0.70	543	Analyst Report Gap Down
CDIO Cardio Diagnostics	2.2418 of 5 stars	$1.54 +4.8%	$8.00 +419.5%	N/A	$14.94M	N/A	0.00	N/A
ICCC ImmuCell	0 of 5 stars	$5.06 -5.4%	N/A	-41.2%	$39.22M	$18.57M	-7.33	60	Positive News Gap Down
NYMX Nymox Pharmaceutical	0 of 5 stars	$0.45 +9.8%	N/A	+5.0%	$40.72M	N/A	-11.25	3	Analyst Report Gap Up
MYMD MyMD Pharmaceuticals	0 of 5 stars	$1.83 -15.7%	N/A	-42.2%	$72.23M	N/A	-5.08	6
VBIV VBI Vaccines	1.8699 of 5 stars	$3.02 +5.2%	$40.00 +1,224.5%	-83.8%	$26.00M	$1.08M	-0.22	149
SNCE Science 37	1.9204 of 5 stars	$0.22 -18.5%	$3.50 +1,487.3%	-93.3%	$25.75M	$70.15M	-0.21	601	Gap Up
IMPL Impel Pharmaceuticals	2.2222 of 5 stars	$1.10 -8.3%	$15.00 +1,261.7%	-82.0%	$26.16M	$12.65M	-0.24	129	Positive News Gap Up

Related Companies and Tools

This page (NASDAQ:BMRA) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biomerica (BMRA) Competitors

BMRA vs. OCX, AWH, TRIB, CDIO, ICCC, NYMX, MYMD, VBIV, SNCE, and IMPL

Biomerica vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA vs. The Competition

Biomerica Competitors List

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info